U.S. markets open in 8 hours 36 minutes

Capricor Therapeutics, Inc. (CAPR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.31+0.25 (+4.94%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close5.06
Open4.87
Bid0.00 x 800
Ask0.00 x 4000
Day's Range4.83 - 5.79
52 Week Range3.13 - 12.32
Volume2,100,706
Avg. Volume489,757
Market Cap121.482M
Beta (5Y Monthly)6.46
PE Ratio (TTM)N/A
EPS (TTM)-0.86
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference
    GlobeNewswire

    Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference

    LOS ANGELES, June 17, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating and preventing a broad spectrum of diseases, announced today that Capricor CEO, Linda Marbán, Ph.D., will provide an update on recent findings after a preliminary review of the Company’s ongoing open-label extension study of the Phase II HOPE-2 trial with lead asset, CAP-100

  • Hedge Funds Are Betting On Capricor Therapeutics, Inc. (CAPR)
    Insider Monkey

    Hedge Funds Are Betting On Capricor Therapeutics, Inc. (CAPR)

    Is Capricor Therapeutics, Inc. (NASDAQ:CAPR) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]

  • Capricor Therapeutics to Participate in BIO Digital 2021 Conference
    GlobeNewswire

    Capricor Therapeutics to Participate in BIO Digital 2021 Conference

    LOS ANGELES, June 10, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that the company will participate in 1x1 meetings with investors and potential partners at BIO Digital 2021 being held June 10-11 and June 14-18, 2021. To schedule a meeting with the Capricor management team at this conference,